Controlling drug design through ‘unnatural’ selection

Darwin probably never envisaged that, 150 years after ‘Origin of the Species’ was published, scientists would be adapting his ideas to improve drug design, but new research from the University of Leeds is doing just that.

Enzymologist Alan Berry and chemist Adam Nelson used ‘directed evolution’ to adapt a natural enzyme to make analogues of the anti-flu drug, Relenza™. The scientists – from Leeds’ Astbury Centre – created enzymes able to control the three-dimensional construction of the drug-like molecules they produced. Controlling the shape of drugs at this level is essential since many therapeutics only work when in one format and, in some cases – such as Thalidomide – the wrong format can have serious side effects. This is the first time that the technique has been used in this way.

Directed evolution mirrors natural evolution, except that the researchers control which properties are passed on to the next ‘generation’. Dr Berry and Professor Nelson made thousands of copies of their target enzyme, each subtly different to the ‘parent’, and then selected the ones that suited their purpose best. They then repeated the process, until, step by step, they had the final enzymes they were looking for.

Dr Berry said: “Enzymes can be engineered using rational design, but it takes a lot of time to amass enough information to use that approach. With directed evolution, you pick randomly from a huge number of copies of the enzyme to find the properties you want. It’s fully automated and very high throughput. Syntheses of anti-flu drugs are complicated, but using this technique you can cut out some of the process – often generating enzymes which are much more efficient than their natural ‘parents’.”

Professor Nelson said: “Directed evolution could help simplify the production process for many drugs already on the market, but it’s unlikely to be used in this way as a new method of synthesis requires approval even for an existing drug. However, in the future, drug design is likely to focus more and more on directed evolution, with a big increase in the number of bio-engineered catalysts created for drug development.”

Dr Berry added: “It is surprising that chemical manufacturers don’t use enzymes more widely as catalysts, as they are environmentally friendly. The main stumbling block has been that enzymes will only carry out very specific reactions. However, we’ve shown that directed evolution allows us to modify natural enzymes as required, opening up the possibility of creating tailored catalysts for a range of industrial chemical syntheses.”

The research was funded by the BBSRC, EPSRC and the Wellcome Trust. The scientists have secured further funding from these agencies to look at adapting enzymes to create more complex sugars, such as di- and tri-saccharides.

Source: University of Leeds

Related stories:

Energy-saving bacteria resist antibiotics
Bacteria save energy by producing proteins that moonlight, having different roles at different times, which may also protect the microbes from being killed. The moonlighting activity of one enzyme from the tuberculosis bacterium makes it partially resistant to a family of broad-spectrum antibiotics, according to a paper published in the September issue of the journal Microbiology.
The good news in our DNA: Defects you can fix with vitamins and minerals
As the cost of sequencing a single human genome drops rapidly, with one company predicting a price of $100 per person in five years, soon the only reason not to look at your "personal genome" will be fear of what bad news lies in your genes.
Researchers stumped by drug addiction paradox
From chocolate and caffeine to nicotine and cocaine, many of our most addictive foods and drugs come from plant toxins. Considering that plants originally developed these toxins to deter herbivorous predators, it’s ironic that humans and other mammals don’t merely tolerate the toxins, but can crave them and even develop dependencies on them.
Winemaking waste proves effective against disease-causing bacteria in early studies
Potential source of next-generation drugs against oral disease: Pinot noir
A class of chemicals in red wine grapes may significantly reduce the ability of bacteria to cause cavities, according to a study published recently in the Journal of Agricultural and Food Chemistry. The findings suggest that specific polyphenols, present in large amounts in fermented seeds and skins cast away after grapes are pressed, interfere with the ability of bacteria to contribute to tooth decay. Beyond cavities, the action of the wine grape-based chemicals may also hold clues for new ways to lessen the ability of bacteria to cause life-threatening, systemic infections.
Discovery of New Antiviral Mechanism in Mammals May Improve Treatment of Hepatitis C Infections
A team of researchers led by biologists at the University of California, San Diego has discovered a completely new mechanism that mammalian cells employ to fight infections of the Hepatitis C virus, which affects approximately 2.7 million Americans and 170 million people worldwide.
New model could improve some drugs' effectiveness
MIT researchers have developed a computer modeling approach that could improve a class of drugs based on antibodies, molecules key to the immune system. The model can predict structural changes in an antibody that will improve its effectiveness.
Using evolution, scientists create a template for many new therapeutic agents
By guiding an enzyme down a new evolutionary pathway, a team of University of Wisconsin-Madison researchers has created a new form of an enzyme capable of producing a range of potential new therapeutic agents with anticancer and antibiotic properties.
Darwin's famous finches and Venter's marine microbes
Although the Galápagos finches were to play a pivotal role in the inception of Darwin’s theory of evolution through natural selection, he had no inkling of their significance when he collected them during his voyage on the HMS Beagle.

News discussion:

Medicine & Health news